SPP1 and chronic obstructive pulmonary disease: We have demonstrated that simvastatin reversed IL-13-suppressed ADA activity in COPD patients that leads to the down-regulation of adenosine signaling and therefore inhibits OPN expression through the direct inhibition of IL-13-activated STAT6 pathway.